ResearchMoz

Stem Cell Therapy Market in Asia-Pacific to 2018 - Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

GBI Research
Published Date » 2012-12-14
No. Of Pages » 112

Stem Cell Therapy Market in Asia-Pacific to 2018 Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity

Summary

GBI Research, the leading business intelligence provider, has released its latest research Stem Cell Therapy Market in Asia-Pacific to 2018 Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity. The report provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

GBI Research analysis finds the stem cell therapy market was valued at $545m in 2012, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10% from 2012 to 2018, to attain a value of $972m in 2018. The market is poised for significant growth in the forecast period due to the anticipated launch of JCR Pharmaceuticals JR-031 (2014) in Japan and FCB Pharmicells Cerecellgram (CCG) (2015) in South Korea. The research is mainly in early stages, with the majority of the molecules being in early stages of development (Phase I/II and Phase II). Phase I/II and Phase II contribute 67% of the pipeline. Stem cell research is dominated by hospitals/universities/institutions, which contribute 63% of the molecules in the pipeline. The dominance of institutional research is attributable to uncertain therapeutic outcomes in stem cell research.The major companies conducting research in India include Reliance Life Sciences and Stempeutics Research Pvt Ltd, among others. The major institutions include PGIMER and AIIMS.

Scope

  • Country analysis of regulatory framework of India, China, South-Korea, Japan and Singapore
  • In-depth information and analysis on the pipeline products expected to bring a shift to the market positions of the leading manufacturers. 
  • Market characterization data for stem cell research for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. 
  • Key drivers and restraints that have a significant impact on the market.
  • Competitive landscape of stem cell research in Asia-Pacific. The key companies discussed in this report are Stempeutics, Reliance Lifesciences, International Stem cell services, Shenzhen Beike Biotechnology, JCR Pharmaceuticals, ES Cells International, Stem Cell Technologies i, Pharmicell and Medipost
  • Key M&A activities, licensing agreements, that have taken place between stem cell companies in 2007 till date.

Reasons to buy

  • Build effective strategies to launch pipeline products by identifying the latest regulatory developments in the leading geographies
  • Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth 
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill their portfolio gaps 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships
  • Develop key strategic initiatives by studying the key strategies of top competitors
  • Reinforce R&D pipelines by identifying licensing strategies for acquiring new delivery mechanisms that have more efficiency and better safety
Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 10

2 Stem Cell Therapy Market in Asia-Pacific to 2018 - Introduction 13

3 Stem Cell Therapy Market in Asia-Pacific to 2018 - Overview 14

3.1 Introduction 14
3.2 Market Characterization and Forecasts - Overview 15
3.2.1 Revenue Forecasts 15
3.2.2 Cost of Therapy 16
3.2.3 Allogeneic and Autologous Share 17
3.2.4 Stem Cell Therapy Patient Pool 18
3.3 Drivers and Barriers 19
3.3.1 Drivers 20
3.3.2 Barriers 20

4 Stem Cell Therapy Market in Asia-Pacific to 2018 - India 21
4.1 Introduction 21
4.2 Regulatory Landscape 21
4.3 Market Characterization and Forecasts - Overview 22
4.3.1 Revenue Forecasts 22
4.3.2 Cost of Therapy 23
4.3.3 Stem Cell Patient Pool 23
4.4 CABG Market Characterization and Forecasts 24
4.4.1 Introduction 24
4.4.2 Revenue Forecasts 24
4.4.3 Cost of Therapy 25
4.4.4 Stem Cell Patient Pool 26
4.5 Type 2 DM Market Characterization and Forecasts 27
4.5.1 Introduction 27
4.5.2 Revenue Forecasts 28
4.5.3 Cost of Therapy 29
4.5.4 Stem Cell Patient Pool 30
4.6 LSCT Market Characterization and Forecasts 31
4.6.1 Introduction 31
4.6.2 Revenue Forecasts 31
4.6.3 Cost of Therapy 32
4.6.4 Stem Cell Patient Pool 33

5 Stem Cell Therapy Market in Asia-Pacific to 2018 - China 34
5.1 Introduction 34
5.2 Regulatory Landscape 34
5.3 Market Characterization and Forecasts - Overview 35
5.3.1 Type 1 DM Market Characterization and Forecasts 35

6 Stem Cell Therapy Market in Asia-Pacific to 2018 - Japan 39
6.1 Introduction 39
6.2 Regulatory Landscape 39
6.3 Steroid Refractory aGvHD Market Characterization and Forecasts 41
6.3.1 Overview 41
6.3.2 Revenue Forecasts 42
6.3.3 Cost of Therapy 43
6.3.4 Stem Cell Patient Pool 44

7 Stem Cell Therapy Market in Asia-Pacific to 2018 - Singapore 45
7.1 Introduction 45
7.2 Regulatory Landscape 45
7.2.1 Ethical, Legal and Social Issues in Human Stem Cell Research, Reproductive and Therapeutic Cloning (June 2002) 46
7.2.2 Human Tissue Research (November 2002) 47
7.2.3 Research Involving Human Subjects (November 2004) 48
7.2.4 Genetic Testing and Genetic Research (November 2005) 49
7.2.5 Personal Information in Biomedical Research (May 2007) 50
7.2.6 Donation of Human Eggs for Research (November 2008) 50
7.2.7 Human-Animal Combinations in Stem Cell Research (September 2010) 50

8 Stem Cell Therapy Market in Asia-Pacific to 2018 - South Korea 51
8.1 Introduction 51
8.2 Regulatory Landscape 51
8.3 Market Characterization and Forecasts - Overview 53
8.3.1 Revenue Forecasts 53
8.3.2 Cost of Therapy 55
8.3.3 Stem Cell Patient Pool 56
8.4 Cupistem Market Characterization and Forecasts 57
8.4.1 Overview 57
8.4.2 Revenue Forecasts 58
8.4.3 Cost of Therapy 59
8.4.4 Stem Cell Patient Pool 60
8.5 HCG-AMI Market Characterization and Forecasts 61
8.5.1 Overview 61
8.5.2 Revenue Forecasts 62
8.5.3 Cost of Therapy 63
8.5.4 Stem Cell Patient Pool 64
8.6 Cartistem Market Characterization and Forecasts 65
8.6.1 Overview 65
8.6.2 Revenue Forecasts 66
8.6.3 Cost of Therapy 67
8.6.4 Stem Cell Patient Pool 68
8.7 CCG Market Characterization and Forecasts 69
8.7.1 Overview 69
8.7.2 Revenue Forecasts 69
8.7.3 Cost of Therapy 70
8.7.4 Stem Cell Patient Pool 71

9 Stem Cell Therapy Market in Asia-Pacific to 2018 - Pipeline Analysis 72
9.1 Pipeline Analysis by Phase 72
9.2 Pipeline Analysis by Sponsors/Collaborators 73
9.3 Pipeline Analysis by Country 74
9.3.1 India Stem Cell R&D Pipeline 75
9.3.2 China Stem Cell R&D Pipeline 77
9.3.3 Japan Stem Cell R&D Pipeline 81
9.3.4 Singapore Stem Cell R&D Pipeline 85
9.3.5 South Korea Stem Cell R&D Pipeline 86
9.3.6 Product Profiles of Promising Molecules 88
9.3.7 Product Profiles of Marketed Products 89

10 Stem Cell Therapy Market in Asia-Pacific to 2018 - Competitive Landscape 91
10.1 Stempeutics Research 91
10.1.1 Overview 91
10.1.2 Product Pipeline 92
10.2 Reliance Life Sciences 93
10.2.1 Overview 93
10.2.2 Product Pipeline 93
10.3 International Stem Cell Services 94
10.3.1 Overview 94
10.3.2 Product Pipeline 94
10.4 Shenzhen Beike Biotechnology 95
10.4.1 Overview 95
10.4.2 Product Pipeline 95
10.5 JCR Pharmaceuticals 96
10.5.1 Overview 96
10.5.2 Product Pipeline 96
10.6 ES Cells International (Subsidiary of BioTime, Inc) 97
10.6.1 Overview 97
10.6.2 Product Pipeline 97
10.7 Stem Cell Technologies i 98
10.7.1 Overview 98
10.7.2 Product Pipeline 98
10.8 Pharmicell 99
10.8.1 Overview 99
10.8.2 Product Pipeline 99
10.9 Medipost 100
10.9.1 Overview 100
10.9.2 Product Pipeline 100

11 Stem Cell Therapy Market in Asia-Pacific to 2018 - Strategic Consolidations 101
11.1 Overview 101
11.2 M&A Deals 102
11.2.1 RNL BIO Acquired 10% Stake in Celltex Therapeutics for $10m - October 28, 2011 102
11.2.2 BioTime Acquired ES Cell International - May 3, 2010 102
11.2.3 BCCL Acquires Stake in Life Cell - May 1, 2007 102
11.3 Licensing Deals 102
11.3.1 RNL BIO Forms Joint Venture to Develop Stem Cell Therapy - September 29, 2011 102
11.3.2 Kiadis Pharma Enters into Licensing Agreement with Hospira for ATIR - January 4, 2011 102
11.3.3 Cipla Enters into Co-Marketing Agreement with Stempeutics - April 27, 2010 102
11.3.4 Teijin Enters into Licensing Agreement with SanBio - March 2, 2010 102
11.3.5 Cleveland BioLabs Enters into Licensing Agreement with Zhejiang Hisun Pharma - September 9, 2009 103
11.3.6 Merck Signs a Licensing Agreement with Japan Tobacco - September 25, 2008 103
11.3.7 ES Cell Enters into Licensing Agreement with ITI Life Sciences - January 31, 2007 103
11.4 Co-Development Deals 103
11.4.1 JCR Pharma Enters into Co-Development Agreement with MediPal - September 13, 2011 103
11.4.2 Athersys Enters into Co-Development Agreement with Pfizer - December 21, 2009 103
11.4.3 Genzyme Enters into Agreement with Osiris Therapeutics - November 4, 2008 104
11.4.4 JCR Pharma Enters into Co-Development Agreement with Mochida Pharma - December 21, 2007 104

12 Stem Cell Therapy Market in Asia-Pacific to 2018 - Appendix 105
12.1 Market Definitions 105
12.2 Abbreviations 105
12.3 Bibliography 107
12.4 Research Methodology 108
12.4.1 Coverage 108
12.4.2 Secondary Research 108
12.4.3 Primary Research 109
12.5 Therapeutic Landscape 109
12.5.2 Market Size by Geography 111
12.6 Geographical Landscape 112
12.7 Pipeline Analysis 112
12.8 Competitive Landscape 112
12.8.1 Expert Panel Validation 112
12.9 Contact Us 112
12.10 Disclaimer 112

List of Tables


Table 1: Stem Cell Therapy Market in Asia-Pacific to 2018, Revenue Forecasts ($m), 2012-2018 15
Table 2: Stem Cell Therapy Market in Asia-Pacific to 2018, Patient Pool for Stem Cell Therapy Forecasts (000), 2012-2018 18
Table 3: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Revenue Forecasts ($m), 2012-2018 22
Table 4: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Patient Pool Forecasts (000), 2012-2018 23
Table 5: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Revenue Forecasts ($000), 2012-2018 24
Table 6: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Cost of Therapy Forecasts ($), 2012-2018 25
Table 7: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Patient Pool Forecasts (Absolute), 2012-2018 26
Table 8: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Revenue Forecasts ($m), 2012-2018 28
Table 9: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Cost of Therapy Forecasts ($), 2012-2018 29
Table 10: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Patient Pool Forecasts (000), 2012-2018 30
Table 11: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Revenue Forecasts ($000), 2012-2018 31
Table 12: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Cost of Therapy Forecasts ($), 2012-2018 32
Table 13: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Patient Pool Forecasts (Absolute), 2012-2018 33
Table 14: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Revenue Forecasts ($m), 2012-2018 36
Table 15: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Cost of Therapy Forecasts ($), 2012-2018 37
Table 16: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Patient Pool Forecasts (000), 2012-2018 38
Table 17: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Revenue Forecasts ($m), 2014-2018 42
Table 18: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Cost of Therapy Forecasts ($), 2014-2018 43
Table 19: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Patient Pool for Stem Cell Therapy Forecasts (Absolute), 2014-2018 44
Table 20: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Revenue Forecasts ($m), 2012-2018 53
Table 21: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Patient Pool for Stem Cell Therapy, Forecasts (Absolute), 2012-2018 56
Table 22: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Revenue Forecasts ($m), 2012-2018 58
Table 23: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Cost of Therapy Forecasts ($), 2012-2018 59
Table 24: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Patient Pool Forecasts (Absolute), 2012-2018 60
Table 25: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Revenue Forecasts ($m), 2012-2018 62
Table 26: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Cost of Therapy Forecasts ($), 2012-2018 63
Table 27: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Patient Forecasts, 2012-2018 64
Table 28: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Revenue Forecasts ($m), 2012-2018 66
Table 29: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Cost of Therapy Forecasts ($), 2012-2018 67
Table 30: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Patient Pool Forecasts (Absolute), 2012-2018 68
Table 31: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Revenue Forecasts ($m), 2015-2018 69
Table 32: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Cost of Therapy Forecasts ($), 2015-2018 70
Table 33: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Patient Pool Forecasts (Absolute), 2015-2018 71
Table 34: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Phase, 2012 72
Table 35: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Sponsors/Collaborators, 2012 73
Table 36: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Country, 2012 74
Table 37: Stem Cell Therapy Market in Asia-Pacific to 2018, India, R&D Pipeline Analysis by Phase, 2012 75
Table 38: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Phase II/III Pipeline Analysis, 2012 76
Table 39: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Phase II Pipeline Analysis, 2012 76
Table 40: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Phase I/II Pipeline Analysis, 2012 76
Table 41: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Unknown Phase, 2012 76
Table 42: Stem Cell Therapy Market in Asia-Pacific to 2018, China, R&D Pipeline Analysis by Phase, 2012 77
Table 43: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Post-Market Pipeline Analysis, 2012 78
Table 44: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Phase II Pipeline Analysis, 2012 78
Table 45: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Phase I/II Pipeline Analysis, 2012 79
Table 46: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Phase I Pipeline Analysis, 2012 79
Table 47: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Clinical Pre-Test Pipeline Analysis, 2012 80
Table 48: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Unknown Phase, 2012 80
Table 49: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, R&D Pipeline Analysis by Phase, 2012 81
Table 50: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase III Stage Molecules Pipeline Analysis, 2012 82
Table 51: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase II/III Stage Molecules Pipeline Analysis, 2012 82
Table 52: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase II Stage Molecules Pipeline Analysis, 2012 83
Table 53: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase I/II Stage Molecules Pipeline Analysis, 2012 84
Table 54: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, Phase I Stage Molecules Pipeline Analysis, 2012 84
Table 55: Stem Cell Therapy Market in Asia-Pacific to 2018, Singapore, Phase I/II Stage Molecules Pipeline Analysis, 2012 85
Table 56: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, R&D Pipeline Analysis by Phase, 2012 86
Table 57: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase III Molecules Pipeline Analysis, 2012 87
Table 58: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase II/III Molecules Pipeline Analysis, 2012 87
Table 59: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase II Molecules Pipeline Analysis, 2012 87
Table 60: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase I/II Molecules Pipeline Analysis, 2012 87
Table 61: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Phase I Molecules Pipeline Analysis, 2012 88
Table 62: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Unknown Phase, 2012 88
Table 63: Stem Cell Therapy Market in Asia-Pacific to 2018, Stempeutics, R&D Pipeline, 2012 92
Table 64: Stem Cell Therapy Market in Asia-Pacific to 2018, Reliance Life Sciences, R&D Pipeline, 2012 93
Table 65: Stem Cell Therapy Market in Asia-Pacific to 2018, International Stem Cell Services Limited, R&D Pipeline, 2012 94
Table 66: Stem Cell Therapy Market in Asia-Pacific to 2018, Shenzhen Beike Biotechnology R&D Pipeline, 2012 95
Table 67: Stem Cell Therapy Market in Asia-Pacific to 2018, JCR Pharmaceuticals Co. Ltd, R&D Pipeline, 2012 96
Table 68: Stem Cell Therapy Market in Asia-Pacific to 2018, Pharmicell, R&D Pipeline, 2012 99
Table 69: Stem Cell Therapy Market in Asia-Pacific to 2018, Medipost, R&D Pipeline, 2012 100
Table 70: Stem Cell Therapy Market in Asia-Pacific to 2018, Strategic Consolidations Overview, 2007-2012 101

List of Figures


Figure 1: Stem Cell Therapy Market in Asia-Pacific to 2018, Overview, 2012 14
Figure 2: Stem Cell Therapy Market in Asia-Pacific to 2018, Revenue Forecasts ($m), 2012-2018 15
Figure 3: Stem Cell Therapy Market in Asia-Pacific to 2018, Cost of Therapy Overview ($), 2012 16
Figure 4: Stem Cell Therapy Market in Asia-Pacific to 2018, Allogeneic vs. Autologous (%), 2012 17
Figure 5: Stem Cell Therapy Market in Asia-Pacific to 2018, Patient Pool for Stem Cell Therapy Forecasts (000), 2012-2018 18
Figure 6: Stem Cell Therapy Market in Asia-Pacific to 2018, Drivers and Barriers, 2012 19
Figure 7: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Revenue Forecasts ($m), 2012-2018 22
Figure 8: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Cost of Therapy Overview ($), 2012 23
Figure 9: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Patient Pool Forecasts (000), 2012-2018 23
Figure 10: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Revenue Forecasts ($000), 2012-2018 24
Figure 11: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Cost of Therapy Forecasts ($), 2012-2018 25
Figure 12: Stem Cell Therapy Market in Asia-Pacific to 2018, India, CABG Patient Pool Forecasts (Absolute), 2012-2018 26
Figure 13: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Revenue Forecasts ($m), 2012-2018 28
Figure 14: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Cost of Therapy Forecasts ($), 2012-2018 29
Figure 15: Stem Cell Therapy Market in Asia-Pacific to 2018, India, Type 2 DM Patient Pool Forecasts (000), 2012-2018 30
Figure 16: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Revenue Forecasts ($000), 2012-2018 31
Figure 17: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Cost of Therapy Forecasts ($), 2012-2018 32
Figure 18: Stem Cell Therapy Market in Asia-Pacific to 2018, India, LSCT Patient Pool Forecasts (Absolute), 2012-2018 33
Figure 19: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Regulatory Framework Timeline, 1998-2009 34
Figure 20: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Revenue Forecasts ($m), 2012-2018 36
Figure 21: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Cost of Therapy Forecasts ($), 2012-2018 37
Figure 22: Stem Cell Therapy Market in Asia-Pacific to 2018, China, Type 1 DM Patient Pool Forecasts (000), 2012-2018 38
Figure 23: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, MHLW Stem Cell Guidelines, 2010 39
Figure 24: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, JR-031 Overview, 2012 41
Figure 25: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Revenue Forecasts ($m), 2014-2018 42
Figure 26: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Cost of Therapy Forecasts ($), 2014-2018 43
Figure 27: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, aGvHD Patient Pool for Stem Cell Therapy Forecasts (Absolute), 2014-2018 44
Figure 28: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Stem Cell Therapeutics Approval Process, 2011 51
Figure 29: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Biopharmaceutical Implementation Strategies, 2011 52
Figure 30: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Revenue Forecasts ($m), 2012-2018 53
Figure 31: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Autologous and Allogeneic Share (%), 2012 54
Figure 32: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Marketed Products Share (%), 2012 and 2018 54
Figure 33: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cost of Therapy ($), Overview, 2012 55
Figure 34: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Patient Pool for Stem Cell Therapy, Forecasts (Absolute), 2012-2018 56
Figure 35: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Revenue Forecasts ($m), 2012-2018 58
Figure 36: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Cost of Therapy Forecasts ($), 2012-2018 59
Figure 37: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cupistem Patient Pool Forecasts (Absolute), 2012-2018 60
Figure 38: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Revenue Forecasts ($m), 2012-2018 62
Figure 39: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Cost of Therapy Forecasts ($), 2012-2018 63
Figure 40: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, HCG-AMI Patient Forecasts (Absolute), 2012-2018 64
Figure 41: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Revenue Forecasts ($m), 2012-2018 66
Figure 42: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Cost of Therapy Forecasts ($), 2012-2018 67
Figure 43: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, Cartistem Patient Pool Forecasts (Absolute), 2012-2018 68
Figure 44: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Revenue Forecasts ($m), 2015-2018 69
Figure 45: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Cost of Therapy Forecasts ($), 2015-2018 70
Figure 46: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, CCG Patient Pool Forecasts (Absolute), 2015-2018 71
Figure 47: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Phase (%), 2012 72
Figure 48: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Sponsors/Collaborators (%), 2012 73
Figure 49: Stem Cell Therapy Market in Asia-Pacific to 2018, R&D Pipeline Analysis by Country (%), 2012 74
Figure 50: Stem Cell Therapy Market in Asia-Pacific to 2018, India, R&D Pipeline Analysis by Phase (%), 2012 75
Figure 51: Stem Cell Therapy Market in Asia-Pacific to 2018, China, R&D Pipeline Analysis by Phase (%), 2012 77
Figure 52: Stem Cell Therapy Market in Asia-Pacific to 2018, Japan, R&D Pipeline Analysis by Phase (%), 2012 81
Figure 53: Stem Cell Therapy Market in Asia-Pacific to 2018, South Korea, R&D Pipeline Analysis by Phase (%), 2012 86
Figure 54: Stem Cell Therapy Market in Asia-Pacific to 2018, Stempeutics, Overview, 2012 91
Figure 55: Stem Cell Therapy Market in Asia-Pacific to 2018, Reliance Life Sciences, Overview, 2012 93
Figure 56: Stem Cell Therapy Market in Asia-Pacific to 2018, International Stem Cell Services, Overview, 2012 94
Figure 57: Stem Cell Therapy Market in Asia-Pacific to 2018, Shenzhen Beike Biotechnology Overview, 2012 95
Figure 58: Stem Cell Therapy Market in Asia-Pacific to 2018, JCR Pharmaceuticals Overview, 2012 96
Figure 59: Stem Cell Therapy Market in Asia-Pacific to 2018, ES Cells International, Overview, 2012 97
Figure 60: Stem Cell Therapy Market in Asia-Pacific to 2018, Stem Cell Technologies i, Overview, 2012 98
Figure 61: Stem Cell Therapy Market in Asia-Pacific to 2018, Pharmicell Overview, 2012 99
Figure 62: Stem Cell Therapy Market in Asia-Pacific to 2018, Medipost, Overview, 2012 100
Figure 63: Stem Cell Therapy Market in Asia-Pacific to 2018, Strategic Consolidations Overview (%), 2007-2012 101
Figure 64: GBI Research Market Forecasting Model 111

Upcoming Reports:

Micro Servers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018
By - Transparency Market Research
A micro server is a small server appliance that works like a server. A server is a physical computer dedicated to run one or more services as a host to serve the needs of the users of other computers on a network. Micro servers are off-the-rack appliances that are specifically designed to process low intensive workloads such as lightweight web serving, simple content delivery nodes, and low end dedicated hosting, with easy installation and maintenance. It comes with preinstalled operating system, hardware and software  configured by the manufacturer. A micro...
ROADM WSS Component Market - Global Industry Size, Market Share, Trends, Analysis And Forecasts 2012 - 2018
By - Transparency Market Research
ROADM is a system that allows flexible, precise, and remote selection of wavelengths transiting a given intermediate node on network for dropping or adding. ROADM components allow access to any wavelength passing through node. This can be done for adding or modifying the data before transmitting to the next node. ROADM components also allows interconnection of multiple intersecting networks at optical level preventing the expense and complexity of OEO conversions to setting up interconnection.  The key factor contributing to growth of ROADM WSS component market is the...
Fishing Equipments Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
The fishing equipments can be segmented into following product categories: reels and poles, rods, lures, fishing lines, flies & baits, hooks, tackle boxes, tools & pliers, rigs, sinkers, tippets & swivels. The fishing techniques include angling, trolling, long line fishing and snagging. Depending upon the technique of fishing various appropriate tools have been developed. Globally fishing is a large market and continues to grow at a rapid pace. Increasing population has its own demands for food products and fish & fish products form a large segment in people’s food...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

India is Facing a Cancer Crisis
Apr 15, 2014  
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai.  The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis.  Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014  
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods.  This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...
USFDA Approves Lupins Generic Diabetic Drug
Apr 10, 2014  
The United States Food and Drugs Administration (USFDA) has finally approved Lupin Pharmaceuticals Inc (LPI), the American subsidiary of Indian drug manufacturers Lupin Ltd, to sell Pioglitazone Tablets in the U.S market. The approval has been granted first for fiscal 2015.  Pioglitazone is a generic medicine used for managing diabetes and is a version of Actos tablets...
Infrared Sensors can Soon Be Used to Develop Night-Vision Lenses - A New Discovery Confirms
Apr 8, 2014  
People who fear the dark may soon have a reason to rejoice – an infrared sensor that can eventually be used for mechanizing night-vision lenses has been developed. This effectively means that one can also see through dark with the help of these lenses.  This technology seems possible all due to graphene, a layer of tightly packed carbon atoms that has allowed the creation of...
Ontarios thanks Sustainable Development Technology Canada for Clean Tech Ecosystem Movements
Apr 8, 2014  
Sustainable Development Technology Canada has leveraged an extra $2.2 billion in funding from project partners that also includes global clean technology companies.  Sustainable Development Technology Canada (SDTC) is energizing and evolving the development and demonstration of a clean technology ecosystem. They are the vital contributors to the prominent concentration of clean...